Eli Lilly Weight Loss Stock Drops 2.6% on Slow Foundayo Launch

How is Eli Lilly performing in the market?

During Tuesday afternoon trading on Wall Street, shares of Eli Lilly and Company faced some downward pressure, dropping 2.57% to trade around $1152.21. This minor retreat was partly influenced by broader healthcare sector movements, including weaker-than-expected earnings from hospital operator HCA Healthcare. However, the temporary dip has not dampened the enthusiasm of major financial institutions. Analyst Courtney Breen from Bernstein maintained an Outperform rating on the stock and raised the price target from $1300 to $1385, signaling robust confidence in the firm’s long-term commercial trajectory.

This bullish outlook is heavily tied to the massive potential of the Eli Lilly Weight Loss pipeline. The global market for these therapies is currently on track to reach nearly $100 billion within the next few years. While Danish rival Novo Nordisk was the first to establish a major foothold with its GLP-1 blockbusters, Eli Lilly has successfully captured the leadership position in the United States, securing an impressive 60% share of the domestic market.

Is the slow launch of Foundayo a threat?

Despite its overall market leadership, some investors have expressed concern over a recent trend in Eli Lilly’s newly launched oral GLP-1 medication, Foundayo, which received regulatory approval this spring. According to prescription tracking data from IQVIA, weekly prescription growth for Foundayo has remained relatively flat over a five-week period. In its 13th week post-launch, the drug recorded 19,550 prescriptions.

In comparison, Novo Nordisk’s competing oral pill, Wegovy, achieved over 105,000 prescriptions at the same point in its launch cycle. This disparity has raised questions about whether the Eli Lilly Weight Loss portfolio is facing unexpected friction in the oral segment. However, industry experts point out key structural differences. Oral Wegovy utilizes semaglutide, a molecule already highly familiar to doctors and patients, whereas Foundayo is an entirely new GLP-1 compound that requires a longer educational curve for prescribing physicians.

Why does Eli Lilly maintain a competitive edge?

Furthermore, insurance coverage dynamics played a major role in the initial launch momentum. While major pharmacy benefit managers provided immediate coverage for Novo Nordisk’s oral offering from week one, insurance coverage for Foundayo was established much later. Over time, Eli Lilly’s oral treatment is expected to gain significant traction due to its superior patient convenience: unlike oral Wegovy, Foundayo does not require strict food and beverage restrictions before administration.

In the injectable space, Eli Lilly’s tirzepatide (sold as Zepbound for weight loss and Mounjaro for type 2 diabetes) continues to outperform. Head-to-head clinical data shows that Zepbound helped patients lose an average of 20% of their body weight at 72 weeks, compared to 13% for Novo Nordisk’s injectable Wegovy. This clinical superiority, combined with expanded manufacturing capacity to resolve past shortages, ensures that the core Eli Lilly Weight Loss franchise remains highly lucrative for long-term investors.

Related Coverage

For investors tracking the broader regulatory and market environment, understanding policy shifts is crucial. The potential expansion of government reimbursement is detailed in Eli Lilly Medicare Obesity: $15B Market Boom Builds, which highlights how federal coverage could unlock massive new patient demographics. Meanwhile, the broader biotech sector continues to experience high volatility, as explored in Biogen LEQEMBI Approval: Stock Plunges 8% Despite FDA Greenlight, demonstrating how even positive regulatory milestones can trigger unexpected market sell-offs.